BIO-TECHNE Corp Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31)
BIO-TECHNE Corp (TECH) had Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) of $298.00 million as of 2013-03-31, per its 10-Q filed 2013-05-10.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesFairValueDisclosure · last filed 2013-05-10
- 2013-03-31: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $298.00M.
- 2012-12-31: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $271.00M.
- 2012-06-30: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $296.00M; Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) as first filed $296.28M.
- 2011-06-30: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $195.19M.
| Period end | Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) | Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) as first filed |
|---|---|---|
| 2013-03-31 | $298.00M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $271.00M 10-Q · filed 2013-02-11 | |
| 2012-06-30 | $296.00M 10-Q · filed 2013-05-10 | $296.28M 10-K · filed 2012-08-29 |
| 2011-06-30 | $195.19M 10-K · filed 2012-08-29 | |
| 2010-06-30 | $215.84M 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |